Pharmacotherapy of personality disorders

References

• Aberg-Wistedt A., Agren H., Ekselius L., Bengtsson F., Akerblad A. C. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. Journal of Clinical Psychopharmacology 2000; 20: 645–652
   PubMed Web of Science ®Google Scholar
• Akiskal H. S. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatrica Scandinavica 2004; 110: 401–407
   PubMed Web of Science ®Google Scholar
• Aldenkamp A. P., Arends J., Bootsma H. P. R., Diepman L., Hulsman J., Lambrechts D., Leenen L., Majoie M., Schellekens A., de Vocht J. Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers. Epilepsia 2002; 43: 19–26
   PubMedGoogle Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. American Journal of Psychiatry 2001; 158(October Suppl)1–52
   Google Scholar
• Barratt E. S., Kent T. A., Bryant S. G., Felthous A. R. A controlled trial of phenytoin in impulsive aggression. Journal of Clinical Psychopharmacology 1991; 11: 388–389
   PubMed Web of Science ®Google Scholar
• Barratt E. S., Stanford M. S., Felthous A. R., Kent T. A. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. Journal of Clinical Psychopharmacology 1997; 17: 341–349
   PubMed Web of Science ®Google Scholar
• Battaglia J., Wolff T. K., Wagner-Johnson D. S., Rush A. J., Carmody T. J., Basco M. R. Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology 1999; 14: 361–372
   PubMedGoogle Scholar
• Bender D. S., Dolan R. T., Skodol A. E., Sanislow C. A., Dyck I. R., McGlashan T. H., Shea M. T., Zanarini M. C., Oldham J. M., Gunderson J. G. Treatment utilization by patients with personality disorders. American Journal of Psychiatry 2001; 158: 295–302
   PubMed Web of Science ®Google Scholar
• Berger P., Sachs G., Amering M., Holzinger A., Bankier B., Katschnig H. Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder. Journal of Affective Disorders 2004; 80: 75–78
   PubMed Web of Science ®Google Scholar
• Bernstein D. P., Kasapis C., Bergman A., Weld E., Mitropoulou V., Horvath T., Klar H. M., Silverman J., Siever L. J. Assessing axis II disorders by informant interview. Journal of Personal Disorders 1997; 11: 158–167
   PubMed Web of Science ®Google Scholar
• Bieling P. J., MacQueen G. M., Marriot M. J., Robb J. C., Begin H., Joffe R. T., Young L. T. Longitudinal outcome in patients with bipolar disorder assessed by life-charting is influenced by DSM-IV personality disorder symptoms. Bipolar Disorders 2003; 5: 14–21
   PubMedGoogle Scholar
• Black K. J., Sheline Y. I. Personality disorder scores improve with effective pharmacotherapy of depression. Journal of Affective Disorders 1997; 43: 11–18
   PubMed Web of Science ®Google Scholar
• Bogenschutz M. P., Nurnberg G. H. Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 2004; 65: 104–109
   PubMed Web of Science ®Google Scholar
• Bohus M. J., Landwehrmeyer G. B., Stiglmayr C. E., Limberger M. F., Bohme R., Schmahl C. G. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. Journal of Clinical Psychiatry 1999; 60: 598–603
   PubMed Web of Science ®Google Scholar
• Bohus M., Schmahl C., Lieb K. New developments in the neurobiology of borderline personality disorder. Current Psychiatry Reports 2004; 6: 43–50
   PubMedGoogle Scholar
• Bolton S., Gunderson J. G. Distinguishing borderline personality disorder from bipolar disorder: differential diagnosis and implications. American Journal of Psychiatry 1996; 153: 1202–1207
   PubMed Web of Science ®Google Scholar
• Brambilla P., Soloff P. H., Sala M., Nicoletti M. A., Keshavan M. S., Soares J. C. Anatomical MRI study of borderline personality disorder patients. Psychiatry Research 2004; 131: 125–133
   PubMed Web of Science ®Google Scholar
• Brendel G. R., Stern E., Silbersweig D. A. Defining the neurocircuitry of borderline personality disorder: Functional neuroimaging approaches. Development and Psychopathology 2005; 17: 1197–1206
   PubMed Web of Science ®Google Scholar
• Cavedini P., Erzegovesi S., Ronchi P., Bellodi L. Predictive value of Obsessive-Compulsive Personality Disorder in antiobsessional pharmacological treatment. European Neuropsychopharmacology 1997; 7: 45–49
   PubMedGoogle Scholar
• Coccaro E. F., Kavoussi R. J. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Archives of General Psychiatry 1997; 54: 1081–1088
   PubMed Web of Science ®Google Scholar
• Coccaro E. F., Kavoussi R. J., Hauger R. L. Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. International Clinical Psychopharmacology 1995; 10: 177–179
   PubMedGoogle Scholar
• Coccaro E. F., Kavoussi R. J., Hauger R. L. Serotonin function and antiaggressive response to fluoxetine: A pilot study. Biological Psychiatry 1997; 42: 546–552
   PubMedGoogle Scholar
• Coccaro E. F., Siever L. J., Klar H. M., Maurer G., Cochrane K., Cooper T. B., Mohs R. C., Davis K. L. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry 1989; 46: 587–599
   PubMed Web of Science ®Google Scholar
• Cohen L. J., Kingston P., Bell A., Kwon J., Aronowitz B., Hollander E. Comorbid personality impairment in body dysmorphic disorder. Comprehensive Psychiatry 2000; 41: 4–12
   PubMedGoogle Scholar
• Cornelius J. R., Soloff P. H., Perel J. M., Ulrich R. F. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. American Journal of Psychiatry 1993; 150: 1843–1848
   PubMed Web of Science ®Google Scholar
• Cowdry R. W., Gardner D. L. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry 1988; 45: 111–119
   PubMed Web of Science ®Google Scholar
• de la Fuente J. M., Lotstra F. A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology 1994; 4: 479–486
   PubMed Web of Science ®Google Scholar
• Ekselius L., von Knorring L. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. International Clinical Psychopharmacology 1998; 13: 205–211
   PubMedGoogle Scholar
• Enns M. W., Swenson J. R., McIntyre R. S., Swinson R. P., Kennedy S. H., CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders: vii. comorbidity. Canadian Journal of Psychiatry 2001; 46(Suppl. 1)77S–90S
   PubMed Web of Science ®Google Scholar
• Evenden J. Impulsivity: a discussion of clinical and experimental findings. Journal of Psychopharmacology 1999; 13: 180–192
   PubMed Web of Science ®Google Scholar
• Fahlén T. Personality traits in social phobia, II: changes during drug treatment. Journal of Clinical Psychiatry 1995; 56: 569–573
   PubMed Web of Science ®Google Scholar
• Faltus F. J. The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. American Journal of Psychiatry 1984; 141: 802–803
   PubMed Web of Science ®Google Scholar
• Fava M., Bouffides E., Pava J. A., McCarthy M. K., Steingard R. J., Rosenbaum J. F. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychotherapy and Psychosomatics 1994; 62: 160–167
   PubMedGoogle Scholar
• Fava M., Farabaugh A. H., Sickinger A. H., Wright E., Alpert J. E., Sonawalla S., Nierenberg A. A., Worthington J. J., 3rd. Personality disorders and depression. Psychological Medicine 2002; 32: 1049–1057
   PubMed Web of Science ®Google Scholar
• Frankenburg F. R., Zanarini M. C. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry 2002; 63: 442–446
   PubMed Web of Science ®Google Scholar
• Friedel R. O. Dopamine dysfunction in borderline personality disorder: A hypothesis. Neuropsychopharmacology 2004; 29: 1029–1039
   PubMed Web of Science ®Google Scholar
• Gardner D. L., Cowdry R. W. Alprazolam-induced dyscontrol in borderline personality disorder. American Journal of Psychiatry 1985; 142: 98–100
   PubMed Web of Science ®Google Scholar
• Gardner D. L., Cowdry R. W. Development of melancholia during carbamazepine treatment in borderline personality disorder. Journal of Clinical Psychopharmacology 1986a; 6: 236–239
   PubMed Web of Science ®Google Scholar
• Gardner D. L., Cowdry R. W. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry 1986b; 143: 519–522
   PubMed Web of Science ®Google Scholar
• Gasperini M., Scherillo P., Manfredonia M. G., Franchini L., Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. European Neuropsychopharmacology 1993; 3: 103–110
   PubMedGoogle Scholar
• Geddes J. R., Burgess S., Hawton K., Jamison K., Goodwin G. M. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. American Journal of Psychiatry 2004; 161: 217–222
   PubMedGoogle Scholar
• Goldberg S. C., Schulz S. C., Resnick R. J., Hamer R. M., Schulz P. M. Differential prediction of response to thiothixene and placebo in borderline and schizotypal personality disorders. Psychopharmacology Bulletin 1987; 23: 342–346
   PubMedGoogle Scholar
• Goldberg S. C., Schulz S. C., Schulz P. M., Resnick R. J., Hamer R. M., Friedel R. O. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Archives of General Psychiatry 1986; 43: 680–686
   PubMed Web of Science ®Google Scholar
• Gollan J. K., Lee R., Coccaro E. F. Development, psychopathology and neurobiology of aggression. Development and Psychopathology 2005; 17: 1151–1171
   PubMed Web of Science ®Google Scholar
• Goodman M., Mitropoulou V., New A. S., Koenigsberg H. W., Siever L. J. Frontal cortex dysfunction and subcortical dopaminergic activity in schizophrenia spectrum. Biological Psychiatry 2000; 47: S34
   PubMedGoogle Scholar
• Goodman M., New A. Impulsive aggression in borderline personality disorder. Current Psychiatry Reports 2000; 2: 56–61
   PubMedGoogle Scholar
• Goodman M., New A., Siever L. Trauma, genes, and the neurobiology of personality disorders. Annals of the New York Academy of Sciences 2004; 1032: 104–116
   PubMed Web of Science ®Google Scholar
• Griengl H., Sendera A., Dantendorfer K. Naltrexone as a treatment of self-injurious behavior – a case report. Acta Psychiatrica Scandinavica 2001; 103: 234–236
   PubMed Web of Science ®Google Scholar
• Gross-Isseroff R., Dillon K. A., Israeli M., Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Research 1990; 530: 312–316
   PubMed Web of Science ®Google Scholar
• Harvey P. D., Keefe R. S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 2001; 158: 176–184
   PubMed Web of Science ®Google Scholar
• Heinze M., Andreae D., Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: State and changes in the last decade. Pharmacopsychiatry 2005; 38: 201–205
   PubMed Web of Science ®Google Scholar
• Henry C., Mitropoulou V., New A. S., Koenigsberg H. W., Silverman J., Siever L. J. Affective instability and impulsivity in borderline personality and bipolar II disorders: Similarities and differences. Journal of Psychiatric Research 2001; 35: 307–312
   PubMed Web of Science ®Google Scholar
• Higgins G. A., Enderlin M., Haman M., Fletcher P. J. The 5-HT2A receptor antagonist M100,907 attenuates motor and ‘impulsive-type’ behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berlin) 2003; 170: 309–319
   PubMedGoogle Scholar
• Hirschfeld R. M., Russell J. M., Delgado P. L., Fawcett J., Friedman R. A., Harrison W. M., Koran L. M., Miller I. W., Thase M. E., Howland R. H., Connolly M. A., Miceli R. J. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. Journal of Clinical Psychiatry 1998; 59: 669–675
   PubMed Web of Science ®Google Scholar
• Hollander E., Allen A., Lopez R. P., Bienstock C. A., Grossman R., Siever L. J., Merkatz L., Stein D. J. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry 2001; 62: 199–203
   PubMed Web of Science ®Google Scholar
• Hollander E., Swann A. C., Coccaro E. F., Jiang P., Smith T. B. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry 2005; 162: 621–624
   PubMed Web of Science ®Google Scholar
• Hollander E., Tracy K. A, Swann A. C., Coccaro E. F., McElroy S. L., Wozniak P., Sommerville K. W., Nemeroff C. B. Divalproex in the treatment of impulsive aggression: Efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28: 1186–1197
   PubMed Web of Science ®Google Scholar
• Houston R. J., Bauer L. O., Hesselbrock V. M. Effects of borderline personality disorder features and a family history of alcohol or drug dependence on P300 in adolescents. International Journal of Psychophysiology 2004; 53: 57–70
   PubMedGoogle Scholar
• Hymowitz P., Frances A., Jacobsberg L. B., Sickles M., Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Comprehensive Psychiatry 1986; 27: 267–271
   PubMed Web of Science ®Google Scholar
• Jensen H. V., Andersen J. An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatrica Scandinavica 1989; 79: 89–93
   PubMedGoogle Scholar
• Joffe R. T., Regan J. J. Personality and response to tricyclic antidepressants in depressed patients. Journal of Nervous and Mental Disease 1989; 177: 745–749
   PubMedGoogle Scholar
• Joyce P. R., Mulder R. T., Luty S. E., McKenzie J. M., Sullivan P. F., Cloninger R. C. Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome. Comprehensive Psychiatry 2003; 44: 35–43
   PubMed Web of Science ®Google Scholar
• Juengling F. D., Schmahl C., Hesslinger B., Ebert D., Bremner J. D., Gostomzyk J., Bohus M., Lieb K. Positron emission tomography in female patients with borderline personality disorder. Journal of Psychiatric Research 2003; 37: 109–115
   PubMed Web of Science ®Google Scholar
• Kato M., Ikenaga Y., Wakeno M., Okugawa G., Nobuhara K., Fukuda T., Fukuda K., Azuma J., Kinoshita T. Controlled clinical comparison of paroxetinee and fluvoxamine considering the serotonin transporter promoter polymorphism. International Clinical Psychopharmacology 2005; 20: 151–156
   PubMed Web of Science ®Google Scholar
• Kayser A., Robinson D. S., Nies A., Howard D. Response to phenelzine among depressed patients with features of hysteroid dysphoria. American Journal of Psychiatry 1985; 142: 486–488
   PubMedGoogle Scholar
• Kemperman I., Russ M. J., Shearin E. Self-injurious behavior and mood regulation in borderline patients. Journal of Personality Disorders 1997; 11: 146–157
   PubMed Web of Science ®Google Scholar
• Keshavan M., Shad M., Soloff P., Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophrenia Research 2004; 71: 97–101
   PubMedGoogle Scholar
• Koenigsberg H. W., Reynolds D., Goodman M., New A. S., Mitropoulou V., Trestman R. L., Silverman J., Siever L .J. Risperidone in the treatment of schizotypal personality disorder. Journal of Clinical Psychiatry 2003; 64: 628–634
   PubMed Web of Science ®Google Scholar
• Kool S., Dekker J., Duijsens I. J., de Jonghe F., Puite B. Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. Journal of Personality Disorders 2003; 17: 60–72
   PubMed Web of Science ®Google Scholar
• Kool S., Schoevers R., de Maat S., Van R., Molenaar P., Vink A., Dekker J. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: A systematic review and meta-analysis. Journal of Affective Disorders 2005; 88: 269–278
   PubMedGoogle Scholar
• Kugaya A., Sanacora G., Staley J. K., Malison R. T., Bozkurt A., Khan S., Anand A., van Dyck C. H., Baldwin R. M., Seibyl J. P., Charney D., Innis R. B. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry 2004; 56: 497–502
   PubMed Web of Science ®Google Scholar
• Kumor K. M., Haertzen C. A., Johnson R. E., Kocher T., Jasinski D. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. Journal of Pharmacology and Experimental Therapeutics 1986; 238: 960–968
   PubMedGoogle Scholar
• Lee M. S., Lee H. Y., Lee H. J., Ryu S. H. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatric Genetics 2004; 14: 111–115
   PubMed Web of Science ®Google Scholar
• Leone N. F. Response of borderline patients to loxapine and chlorpromazine. Journal of Clinical Psychiatry 1982; 43: 148–150
   PubMed Web of Science ®Google Scholar
• Lestra C., d'Amato T., Ghaemmaghami C., Perret-Liaudet A., Broyer M., Renaud B., Dalery J., Chamba G. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Biological Psychiatry 1998; 44: 274–280
   PubMedGoogle Scholar
• Levitt J. J., Westin C. F., Nestor P. G., Estepar R. S., Dickey C. C., Voglmaier M. M., Seidman L. J., Kikinis R., Jolesz F. A., McCarley R. W., Shenton M. E. Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder. Biological Psychiatry 2004; 55: 177–184
   PubMed Web of Science ®Google Scholar
• Liebowitz M. R., Klein D. F. Interrelationship of hysteroid dysphoria and borderline personality disorder. Psychiatric Clinics of North America 1981; 4: 67–87
   PubMed Web of Science ®Google Scholar
• Links P. S, Steiner M., Boiago I., Irwin D. Lithium therapy for borderline patients: preliminary findings. Journal of Personality Disorders 1990; 4: 173–181
   Google Scholar
• Lion J. R. Benzodiazepines in the treatment of aggressive patients. Journal of Clinical Psychiatry 1979; 40: 70–71
   PubMedGoogle Scholar
• Loranger A. W., Lenzenweger M. F., Gartner A. F., Susman V. L., Herzig J., Zammit G. K., Gartner J. D., Abrams R. C., Young R. C. Trait-state artifacts and the diagnosis of personality disorders. Archives of General Psychiatry 1991; 48: 720–728
   PubMed Web of Science ®Google Scholar
• Makela E. H., Moeller K. E., Fullen J. E., Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. Annals of Pharmacotherapy 2006; 40: 49–52
   PubMed Web of Science ®Google Scholar
• Malone K. M., Corbitt E. M., Li S., Mann J. J. Prolactin response to fenfluramine and suicide attempt lethality in major depression. British Journal of Psychiatry 1996; 168: 324–329
   PubMed Web of Science ®Google Scholar
• Marek G. J., Martin-Ruiz R., Abo A., Artigas F. The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005; 30: 2205–2215
   PubMed Web of Science ®Google Scholar
• Markovitz P. J., Calabrese J. R., Schulz S. C., Meltzer H. Y. Fluoxetine in the treatment of borderline and schizotypal personality disorders. American Journal of Psychiatry 1991; 148: 1064–1067
   PubMed Web of Science ®Google Scholar
• Mavissakalian M., Hamann M. S., Jones B. DSM-III personality disorders in obsessive-compulsive disorder: changes with treatment. Comprehensive Psychiatry 1990; 31: 432–437
   PubMed Web of Science ®Google Scholar
• McGee M. D. Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. Journal of Clinical Psychiatry 1997; 58: 32–33
   PubMed Web of Science ®Google Scholar
• McGlashan T. H., Grilo C. M., Skodol A. E., Gunderson J. G., Shea M. T., Morey L. C., Zanarini M. C., Stout R. L. The Collaborative Longitudinal Personality Disorders Study: Baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatrica Scandinavica 2000; 102: 256–264
   PubMed Web of Science ®Google Scholar
• Mehlman P. T., Higley J. D., Faucher I., Lilly A. A., Taub D. M., Vickers J., Suomi S. J., Linnoila M. Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. American Journal of Psychiatry 1994; 151: 1485–1491
   PubMed Web of Science ®Google Scholar
• Minzenberg M. J., Grossman R., New A. S., Mitropoulou V., Yehuda R., Goodman M., Reynolds D. A., Silverman J. M., Coccaro E. F., Marcus S., Siever L. J. Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology 2006; 31: 197–203
   PubMed Web of Science ®Google Scholar
• Montgomery S. A., Montgomery D. Pharmacological prevention of suicidal behavior. Journal of Affective Disorders 1982; 4: 291–298
   PubMed Web of Science ®Google Scholar
• Montgomery S. A., Roy D., Montgomery D. B. The prevention of recurrent suicidal acts. British Journal of Clinical Pharmacology 1983; 15: 183S–188S
   Google Scholar
• Mulder R. T. Personality pathology and treatment outcome in major depression: A review. American Journal of Psychiatry 2002; 159: 359–371
   PubMed Web of Science ®Google Scholar
• Mulder R. T., Joyce P. R., Luty S. E. The relationship of personality disorders to treatment outcome in depressed outpatients. Journal of Clinical Psychiatry 2003; 64: 259–264
   PubMed Web of Science ®Google Scholar
• Nelson J. C., Mazure C. M., Jatlow P. I. Characteristics of desipramine-refractory depression. Journal of Clinical Psychiatry 1994; 55: 12–19
   PubMed Web of Science ®Google Scholar
• New A. S., Hazlett E. A., Buchsbaum M. S., Goodman M., Reynolds D., Mitropoulou V., Sprung L., Shaw R. B., Jr., Koenigsberg H., Platholi J., Silverman J., Siever L. J. Blunted prefrontal cortical 18fluorodeoxyglucose positron emission tomography response to meta-chlorophenylpiperazine in impulsive aggression. Archives of General Psychiatry 2002; 59: 621–629
   PubMed Web of Science ®Google Scholar
• New A. S., Trestman R., Mitropoulou V., Benishay D. S., Coccaro E., Silverman J., Siever L. J. Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry Research 1997; 69: 17–26
   PubMed Web of Science ®Google Scholar
• New A. S., Trestman R., Mitropoulou V., Goodman M., Koenigsberg H., Silverman J., Siever L. J. Low prolactin response to fenfluramine in impulsive aggression. Journal of Psychiatric Research 2004; 38: 223–230
   PubMed Web of Science ®Google Scholar
• Nickel M. K., Nickel C., Kaplan P., Lahmann C., Muhlbacher M., Tritt K., Krawczyk J., Leiberich P. K., Rother W. K., Loew T. H. Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry 2005; 57: 495–499
   PubMed Web of Science ®Google Scholar
• Nickel M. K., Nickel C., Mitterlehner F. O., Tritt K., Lahmann C., Leiberich P. K., Rother W. K., Loew T. H. Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2004; 65: 1515–1519
   PubMed Web of Science ®Google Scholar
• Noyes R., Jr., Reich J., Christiansen J., Suelzer M., Pfohl B., Coryell W. A. Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity. Archives of General Psychiatry 1990; 47: 809–818
   PubMedGoogle Scholar
• Noyes R., Jr., Reich J. H., Suelzer M., Christiansen J. Personality traits associated with panic disorder: Change associated with treatment. Comprehensive Psychiatry 1991; 32: 283–294
   PubMed Web of Science ®Google Scholar
• Ogiso Y., Moriya N., Ikuta N., Maher-Nishizono A., Takase M., Miyake Y., Minakawa K. Relationship between clinical symptoms and EEG findings in borderline personality disorder. Japanese Journal of Psychiatry and Neurology 1993; 47: 37–46
   PubMedGoogle Scholar
• Oldham J. M., Bender D. S., Skodol A. E., Dyck I. R., Sanislow C. A., Yen S., Grilo C. M., Shea M. T., Zanarini M. C., Gunderson J. G., McGlashan T. H. Testing an APA practice guideline: Symptom-targeted medication utilization for patients with borderline personality disorder. Journal of Psychiatric Practice 2004; 10: 156–161
   PubMedGoogle Scholar
• Oquendo M. A., Krunic A., Parsey R. V., Milak M., Malone K. M., Anderson A., van Heertum R. L, John Mann J. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology 2005; 30: 1163–1172
   PubMed Web of Science ®Google Scholar
• Papakostas G. I., Petersen T. J., Farabaugh A. H., Murakami J. L., Pava J. A., Alpert J. E., Fava M., Nierenberg A. A. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 2003; 64: 1357–1361
   PubMedGoogle Scholar
• Paris J. Borderline or bipolar? Distinguishing borderline personality disorder from bipolar spectrum disorders. Harvard Review of Psychiatry 2004; 12: 140–145
   PubMed Web of Science ®Google Scholar
• Paris J. Borderline personality disorder. Canadian Medical Association Journal 2005; 172: 1579–1583
   Web of Science ®Google Scholar
• Parsons B., Quitkin F. M., McGrath P. J., Stewart J. W., Tricamo E., Ocepek-Welikson K., Harrison W., Rabkin J. G., Wager S. G., Nunes E. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacological Bulletin 1989; 25: 524–534
   PubMedGoogle Scholar
• Paykel E. S. Continuation and maintenance therapy in depression. British Medical Bulletin 2001; 57: 145–159
   PubMed Web of Science ®Google Scholar
• Perez V., Bel N., Celada P., Ortiz J., Alvarez E., Artigas F. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. Journal of Clinical Psychopharmacology 1998; 18: 222–230
   PubMed Web of Science ®Google Scholar
• Petersen T., Hughes M., Papakostas G. I., Kant A., Fava M., Rosenbaum J. F., Nierenberg A. A. Treatment-resistant depression and Axis II comorbidity. Psychotherapy and Psychosomatics 2002; 71: 269–274
   PubMed Web of Science ®Google Scholar
• Pfeiffer A., Brantl V., Herz A., Emrich H. M. Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774–776
   PubMed Web of Science ®Google Scholar
• Philipsen A., Richter H., Schmahl C., Peters J., Rusch N., Bohus M., Lieb K. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. Journal of Clinical Psychiatry 2004a; 65: 1414–1419
   PubMed Web of Science ®Google Scholar
• Philipsen A., Schmahl C., Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004b; 37: 196–199
   PubMed Web of Science ®Google Scholar
• Pitchot W., Hansenne M., Pinto E., Reggers J., Fuchs S., Ansseau M. 5-Hydroxytryptamine 1A receptors, major depression, and suicidal behavior. Biological Psychiatry 2005; 58: 854–858
   PubMed Web of Science ®Google Scholar
• Placidi G. P., Oquendo M. A., Malone K. M., Huang Y. Y., Ellis S. P., Mann J. J. Aggressivity, suicide attempts, and depression: Relationship to cerebrospinal fluid monoamine metabolite levels. Biological Psychiatry 2001; 50: 783–791
   PubMed Web of Science ®Google Scholar
• Posner M. I., Rothbart M. K., Vizueta N., Levy K. N., Evans D. E., Thomas K. M., Clarkin J. F. Attentional mechanisms of borderline personality disorder. Proceedings of the National Academy of Sciences 2002; 99: 16366–16370
   PubMed Web of Science ®Google Scholar
• Preston G. A., Marchant B. K., Reimherr F. W., Strong R. E., Hedges D. W. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. Journal of Affective Disorders 2004; 79: 297–303
   PubMedGoogle Scholar
• Reich J. H. Effect of DSM-III personality disorders on outcome of tricyclic antidepressant-treated nonpsychotic outpatients with major or minor depressive disorder. Psychiatry Research 1990; 32: 175–181
   PubMedGoogle Scholar
• Reich J., Noyes R., Jr., Coryell W., O'Gorman T. W. The effect of state anxiety on personality measurement. American Journal of Psychiatry 1986; 143: 760–763
   PubMed Web of Science ®Google Scholar
• Rifkin A., Quitkin F., Carrillo C., Blumberg A. G., Klein D. F. Lithium carbonate in emotionally unstable character disorder. Archives of General Psychiatry 1972; 27: 519–523
   PubMed Web of Science ®Google Scholar
• Rinne T., van den Brink W., Wouters L., van Dyck R. SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry 2002; 159: 2048–2054
   PubMed Web of Science ®Google Scholar
• Roth A. S., Ostroff R. B., Hoffman R. E. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. Journal of Clinical Psychiatry 1996; 57: 233–237
   PubMed Web of Science ®Google Scholar
• Rüsch N., van Elst L. T., Ludaescher P., Wilke M., Huppertz H. J., Thiel T., Schmahl C., Bohus M., Lieb K., Hesslinger B., Hennig J., Ebert D. A voxel-based morphometric MRI study in female patients with borderline personality disorder. Neuroimage 2003; 20: 385–392
   PubMed Web of Science ®Google Scholar
• Russ M. J., Campbell S. S., Kakuma T., Harrison K., Zanine E. EEG theta activity and pain insensitivity in self-injurious borderline patients. Psychiatry Research 1999; 89: 201–214
   PubMed Web of Science ®Google Scholar
• Russ M. J., Roth S. D., Lerman A., Kakuma T., Harrison K., Shindledecker R. D., Hull J., Mattis S. Pain perception in self-injurious patients with borderline personality disorder. Biological Psychiatry 1992; 32: 501–511
   PubMed Web of Science ®Google Scholar
• Russell J. M., Kornstein S. G., Shea M. T., McCullough J. P., Harrison W. M., Hirschfeld R. M., Keller M. B. Chronic depression and comorbid personality disorders: Response to sertraline versus imipramine. Journal of Clinical Psychiatry 2003; 64: 554–561
   PubMed Web of Science ®Google Scholar
• Salzman C., Wolfson A. N., Schatzberg A., Looper J., Henke R., Albanese M., Schwartz J., Miyawaki E. Effects of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology 1995; 15: 23–29
   PubMed Web of Science ®Google Scholar
• Samuelsson M., Jokinen J., Nordstrom A. L., Nordstrom P. CSF 5-HIAA, suicide intent and hopelessness in the prediction of early suicide in male high-risk suicide attempters. Acta Psychiatrica Scandinavica 2006; 113: 44–47
   PubMed Web of Science ®Google Scholar
• Sansone R. A., Rytwinski D., Gaither G. A. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Comprehensive Psychiatry 2003; 44: 454–458
   PubMed Web of Science ®Google Scholar
• Saper J. R. Borderline personality, opioids, and naltrexone. Headache 2000; 40: 765–766
   PubMed Web of Science ®Google Scholar
• Saper J. R., Lake A. E., 3rd. Borderline personality disorder and the chronic headache patient: Review and management recommendations. Headache 2002; 42: 663–674
   PubMed Web of Science ®Google Scholar
• Schlaepfer T. E., Strain E. C., Greenberg B. D., Preston K. L., Lancaster E., Bigelow G. E., Barta P. E., Pearlson G. D. Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects. American Journal of Psychiatry 1998; 155: 470–473
   PubMed Web of Science ®Google Scholar
• Schmahl C. Neurobiology of BPD: An update. Presented at Annual Meeting of the American Psychiatric Association, Atlanta, GA, 2005
   Google Scholar
• Schmahl C., Greffrath W., Baumgartner U., Schlereth T., Magerl W., Philipsen A., Lieb K., Bohus M., Treede R. D. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain 2004; 110: 470–479
   PubMedGoogle Scholar
• Schulz S. C., Camlin K. L., Berry S. A., Jesberger J. A. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biological Psychiatry 1999; 46: 1429–1435
   PubMed Web of Science ®Google Scholar
• Serban G., Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. American Journal of Psychiatry 1984; 141: 1455–1458
   PubMed Web of Science ®Google Scholar
• Serretti A., Cusin C., Rossini D., Artioli P., Dotoli D., Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 2004; 129: 36–40
   Google Scholar
• Sheard M. H. Effect of lithium on human aggression. Nature 1971; 230: 113–114
   PubMed Web of Science ®Google Scholar
• Sheard M. H., Marini J. L., Bridges C. I., Wagner E. The effect of lithium on impulsive aggressive behavior in man. American Journal of Psychiatry 1976; 133: 1409–1413
   PubMed Web of Science ®Google Scholar
• Siever L. J., Amin F., Coccaro E. F., Trestman R., Silverman J., Horvath T. B., Mahon T. R., Knott P., Altstiel L., Davidson M. CSF homovanillic acid in schizotypal personality disorder. American Journal of Psychiatry 1993; 150: 149–151
   PubMed Web of Science ®Google Scholar
• Siever L. J., Buchsbaum M. S., New A. S., Spiegel-Cohen J., Wei T., Hazlett E. A., Sevin E., Nunn M., Mitropoulou V. d,l-fenfluramine response in impulsive personality disorder assessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology 1999; 20: 413–423
   PubMed Web of Science ®Google Scholar
• Siever L. J., Davis K. L. A psychobiological perspective on the personality disorders. American Journal of Psychiatry 1991; 148: 1647–1658
   PubMed Web of Science ®Google Scholar
• Siever L. J., Davis K. L. The pathophysiology of schizophrenia disorders: Perspectives from the spectrum. American Journal of Psychiatry 2004; 161: 398–413
   PubMed Web of Science ®Google Scholar
• Simeon D., Stanley B., Frances A., Mann J. J., Winchel R., Stanley M. Self-mutilation in personality disorders: psychological and biological correlates. American Journal of Psychiatry 1992; 149: 221–226
   PubMed Web of Science ®Google Scholar
• Simpson E. B., Yen S., Costello E., Rosen K., Begin A., Pistorello J., Pearlstein T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry 2004; 65: 379–385
   PubMed Web of Science ®Google Scholar
• Slaap B. R., den Boer J. A. The prediction of nonresponse to pharmacotherapy in panic disorder: A review. Depression and Anxiety 2001; 14: 112–122
   PubMed Web of Science ®Google Scholar
• Smith D. J., Muir W. J., Blackwood D. H. Is borderline personality disorder part of the bipolar spectrum?. Harvard Review of Psychiatry 2004; 12: 133–139
   PubMed Web of Science ®Google Scholar
• Soderstrom H., Forsman A. Elevated triiodothyronine in psychopathy – possible physiological mechanisms. Journal of Neural Transmission 2004; 111: 739–744
   PubMedGoogle Scholar
• Soler J., Pascual J. C., Campins J., Barrachina J., Puigdemont D., Alvarez E., Pérez V. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry 2005; 162: 1221–1224
   PubMed Web of Science ®Google Scholar
• Soloff P. H. Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America 2000; 23: 169–192
   PubMed Web of Science ®Google Scholar
• Soloff P. H., Cornelius J., George A., Nathan S., Perel J. M., Ulrich R. F. Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry 1993; 50: 377–385
   PubMed Web of Science ®Google Scholar
• Soloff P. H., George A., Nathan R. S., Schulz P. M., Cornelius J. R., Herring J., Perel J. M. Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. Journal of Clinical Psychopharmacology 1989; 9: 238–246
   PubMedGoogle Scholar
• Soloff P. H., George A., Nathan R. S., Schulz P. M., Perel J. M. Paradoxical effects of amitriptyline on borderline patients. American Journal of Psychiatry 1986a; 143: 1603–1605
   PubMed Web of Science ®Google Scholar
• Soloff P. H., George A., Nathan R. S., Schulz P. M., Perel J. M. Behavioral dyscontrol in borderline patients treated with amitriptyline. Psychopharmacology Bulletin 1987; 23: 177–181
   PubMedGoogle Scholar
• Soloff P. H., George A., Nathan R. S., Schulz P. M., Ulrich R. F., Perel J. M. Amitriptyline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacology Bulletin 1986b; 22: 177–182
   PubMedGoogle Scholar
• Soloff P. H., George A., Nathan R. S., Schulz P. M., Ulrich R. F., Perel J. M. Progress in pharmacotherapy of borderline disorders. Archives of General Psychiatry 1986c; 43: 691–697
   PubMed Web of Science ®Google Scholar
• Stuart S., Simons A. D., Thase M. E., Pilkonis P. Are personality assessments valid in acute major depression?. Journal of Affective Disorders 1992; 24: 281–290
   PubMed Web of Science ®Google Scholar
• Sullivan P. F., Joyce P. R., Mulder R. T. Borderline personality disorder in major depression. Journal of Nervous and Mental Disease 1994; 182: 508–516
   PubMedGoogle Scholar
• Thase M. E., Haight B. R., Richard N., Rockett C. B., Mitton M., Modell J. G., VanMeter S., Harriett A. E., Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 2005; 66: 974–981
   PubMed Web of Science ®Google Scholar
• Thurauf N. J., Washeim H. A. The effects of exogenous analgesia in a patient with borderline personality disorder (BPD). and severe self-injurious behavior. European Journal of Pain 2000; 4: 107–109
   PubMedGoogle Scholar
• Tohen M., Vieta E., Calabrese J., Ketter T. A., Sachs G., Bowden C., Mitchell P. B., Centorrino F., Risser R., Baker R. W., Evans A. R., Beymer K., Dube S., Tollefson G. D., Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 2003; 60: 1079–1088
   PubMed Web of Science ®Google Scholar
• Traskman L., Asberg M., Bertilsson L., Sjostrand L. Monoamine metabolites in CSF and suicidal behavior. Archives of General Psychiatry 1981; 38: 631–636
   PubMed Web of Science ®Google Scholar
• Trestman R. L., Keefe R. S., Mitropoulou V., Harvey P. D., deVegvar M. L., Lees-Roitman S., Davidson M., Aronson A., Silverman J., Siever L. J. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research 1995; 59: 127–136
   PubMed Web of Science ®Google Scholar
• Tritt K., Nickel C., Lahmann C., Leiberich P. K., Rother W. K., Loew T. H., Nickel M. K. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology 2005; 19: 287–291
   PubMed Web of Science ®Google Scholar
• Vaillant G. E., Perry J. C. Personality disorders. Comprehensive textbook of psychiatry, 4th edn, H. I. Kaplan, B. J. Sadock. Williams & Wilkins, Baltimore 1985; 958–986
   Google Scholar
• Verkes R. J, Van der Mast R. C, Hengeveld M. W., Tuyl J. P, Zwinderman A. H., Van Kempen G. M. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. American Journal of Psychiatry 1998; 155: 543–547
   PubMed Web of Science ®Google Scholar
• Virkkunen M., Rawlings R., Tokola R., Poland R. E., Guidotti A., Nemeroff C., Bissette G., Kalogeras K., Karonen S. L., Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Archives of General Psychiatry 1994; 51: 20–27
   PubMed Web of Science ®Google Scholar
• Walsh S. L., Strain E. C., Abreu M. E., Bigelow G. E. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin) 2001; 157: 151–162
   PubMed Web of Science ®Google Scholar
• Westen D. Divergences between clinical and research methods for assessing personality disorders: Implications for research and the evolution of axis II. American Journal of Psychiatry 1997; 154: 895–903
   PubMed Web of Science ®Google Scholar
• Widiger T. A., Shea T. Differentiation of axis I and axis II disorders. Journal of Abnormal Psychology 1991; 100: 399–406
   PubMedGoogle Scholar
• Winstanley C. A., Theobald D. E., Dalley J. W., Glennon J. C., Robbins T. W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: Interactions with global 5-HT depletion. Psychopharmacology (Berlin) 2004; 176: 376–385
   PubMedGoogle Scholar
• Yu Y. W.-Y., Tsai S. J., Chen T. J., Lin C. H., Hong C. J. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Molecular Psychiatry 2002; 7: 1115–1119
   PubMed Web of Science ®Google Scholar
• Zanarini M. C., Frankenburg F. R. Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry 2001; 62: 849–854
   PubMed Web of Science ®Google Scholar
• Zanarini M. C., Frankenburg F. R. Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry 2003; 160: 167–169
   PubMed Web of Science ®Google Scholar
• Zanarini M. C., Frankenburg F. R., Parachini E. A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry 2004; 7: 903–907
   Google Scholar
• Zimmerman M. Diagnosing personality disorders. A review of issues and research methods. Archives of General Psychiatry 1994; 51: 225–245
   PubMed Web of Science ®Google Scholar